The paradoxical effect of parp inhibitor bgp-15 on irinotecan-induced cachexia and skeletal muscle dysfunction

[thumbnail of cancers-12-03810.pdf]
cancers-12-03810.pdf - Published Version (5MB) | Preview
Available under license: Creative Commons Attribution

Campelj, Dean G, Timpani, Cara ORCID: 0000-0003-4567-4319, Petersen, Aaron ORCID: 0000-0003-1508-748X, Hayes, Alan ORCID: 0000-0003-1398-3694, Goodman, Craig ORCID: 0000-0002-5874-7743 and Rybalka, Emma ORCID: 0000-0002-4854-0036 (2020) The paradoxical effect of parp inhibitor bgp-15 on irinotecan-induced cachexia and skeletal muscle dysfunction. Cancers, 12 (12). pp. 1-28. ISSN 2072-6694


Chemotherapy-induced muscle wasting and dysfunction is a contributing factor to cachexia alongside cancer and increases the risk of morbidity and mortality. Here, we investigate the effects of the chemotherapeutic agent irinotecan (IRI) on skeletal muscle mass and function and whether BGP-15 (a poly-(ADP-ribose) polymerase-1 (PARP-1) inhibitor and heat shock protein co-inducer) adjuvant therapy could protect against IRI-induced skeletal myopathy. Healthy 6-week-old male Balb/C mice (n = 24; 8/group) were treated with six intraperitoneal injections of either vehicle, IRI (30 mg/kg) or BGP-15 adjuvant therapy (IRI+BGP; 15 mg/kg) over two weeks. IRI reduced lean and tibialis anterior mass, which were attenuated by IRI+BGP treatment. Remarkably, IRI reduced muscle protein synthesis, while IRI+BGP reduced protein synthesis further. These changes occurred in the absence of a change in crude markers of mammalian/mechanistic target of rapamycin (mTOR) Complex 1 (mTORC1) signaling and protein degradation. Interestingly, the cytoskeletal protein dystrophin was reduced in both IRI-and IRI+BGP-treated mice, while IRI+BGP treatment also decreased β-dystroglycan, suggesting significant remodeling of the cytoskeleton. IRI reduced absolute force production of the soleus and extensor digitorum longus (EDL) muscles, while IRI+BGP rescued absolute force production of the soleus and strongly trended to rescue force output of the EDL (p = 0.06), which was associated with improvements in mass. During the fatiguing stimulation, IRI+BGP-treated EDL muscles were somewhat susceptible to rupture at the musculotendinous junction, likely due to BGP-15’s capacity to maintain the rate of force development within a weakened environment characterized by significant structural remodeling. Our paradoxical data highlight that BGP-15 has some therapeutic advantage by attenuating IRI-induced skeletal myopathy; however, its effects on the remodeling of the cytoskeleton and extracellular matrix, which appear to make fast-twitch muscles more prone to tearing during contraction, could suggest the induction of muscular dystrophy and, thus, require further characterization.

Dimensions Badge

Altmetric Badge

Item type Article
DOI 10.3390/cancers12123810
Official URL
Subjects Historical > FOR Classification > 0601 Biochemistry and Cell Biology
Historical > FOR Classification > 1112 Oncology and Carcinogenesis
Current > Division/Research > Institute for Health and Sport
Keywords cachexia, chemotherapy, muscular dystrophy phenotype, skeletal muscle, cytoskeletal protein dystrophin
Citations in Scopus 3 - View on Scopus
Download/View statistics View download statistics for this item

Search Google Scholar

Repository staff login